Synta Pharmaceuticals Corporation

Other

Madrigal Pharmaceuticals, Inc.

Prcl Research Inc.

Jun Jiang

Shoujun Chen

Lijun Sun

Yu Xie

Christopher Borella

Keizo Koya

Junyi Zhang

Weiwen Ying

Hao Li

Zhi-Qiang Xia

Zhiqiang Xia

Dinesh U Chimmanamada

Kevin Paul Foley

Zhenjian Du

Yaming Wu

Takayo Inoue

Gary Bohnert

Chih-Yi Yu

Mei Zhang

David James

Mats Harald Holmqvist

Mitsunori Ono

Shijie Zhang

Jerome Mahiou

Teresa Kowalczyk-Przewloka

Genliang Lu

Nha Huu Vo

Stefan M Schweizer

Qinglin Che

Dharma Vutukuri

Zhi Qiang Xia

James Loch

Teresa Kowalczyk Przewloka

Sami Osman

The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.

Targeted therapeutics

The invention relates to certain compounds or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.

Compounds for inflammation and immune-related uses

The invention relates to compounds of structural formula (I) and structural formula (VI): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein R, R, R, Z, L, and n are defined herein. Those compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.

Disclosed are compounds and pharmaceutical compositions that are useful for treating a subject with a proliferative disorder, such as cancer. The disclosed compounds and pharmaceutical compositions are also useful for treating disorders responsive to Hsp70 induction and/or natural killer induction.

Compounds for the treatment of proliferative disorders

The invention relates to compounds of structural formula (I) and structural formula (VI): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein R, R, R, Z, L, and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.

The invention relates to compounds of structural formula (I): 

The invention relates to compounds of structural formulas (I) and (XVI): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein X, X, Z, L, L, R, R, R, R, n, q, and t are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.

Thiophene compounds for inflammation and immune-related uses

Disclosed are compounds of formula (IA), formula (IV) or formula (V), wherein the variables are as defined herein, and pharmaceutical compositions containing them which are useful for treating a subject with a proliferative disorder, such as cancer. The disclosed compounds and pharmaceutical compositions are also useful for treating disorders responsive to Hsp70 induction and/or natural killer induction. 

Disclosed are compounds and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also, disclosed are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier.

Compounds for treating proliferative disorders

The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein Y, L, X, X, Z, R, R, and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.

Pyridylphenyl compounds for inflammation and immune-related uses

The present invention is directed to compounds represented by structural formula (I), or a pharmaceutically acceptable salt or a transition metal chelate, coordinate or complex thereof or a transition metal chelate, coordinate or complex of a deprotonated form of the compound. Pharmaceutical composition and method of use for these compounds are also included. 

Sulfonylhydrazide compounds for treating proliferative disorders

Disclosed herein are methods of preparing a bis(thio-hydrazide amides) compounds of the following structural formula: wherein R, R, R, R, R, Rand Rare defined herein. 

Process for preparing bis(thiohydrazide amides)

The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein A, Y, L, R, Wand Ware defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.

Substituted biaryl compounds for inflammation and immune-related uses

The invention relates to compounds of structural formula (I) or (III): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein ring A, X, X, X, X, R, R, Y, Z, L, m and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.

Growing community of inventors

Norwood, MA, United States of America

Jun Jiang